KRAS mutant bowel cancers segregate into two distinct subgroups

被引：0

作者：

Borowsky, J. ^{[1
,2
,3
]}

Su, C. ^{[1
]}

Fennell, L. ^{[1
]}

Burge, M. ^{[4
]}

Liu, J. ^{[2
]}

Costa, A. Dias ^{[8
]}

Ogino, S. ^{[9
,10
,11
]}

Mckeone, D. ^{[2
]}

Olsen, K. ^{[2
]}

Badshah, J. ^{[2
]}

Bond, C. ^{[2
]}

Nowlan, B. ^{[2
]}

Tria, S. ^{[2
]}

Laki, V. ^{[2
]}

Walker, N. ^{[6
]}

Brown, I. ^{[6
]}

Bettington, M. ^{[6
]}

Leggett, B. ^{[2
,5
]}

Whitehall, V. ^{[2
,7
]}

机构：

[1] Queensland Hlth, Pathol Queensland, Brisbane, Qld, Australia

[2] QIMR Berghofer Med Res Inst, Brisbane, Qld, Australia

[3] Univ Queensland, Sch Med, Brisbane, Australia

[4] Royal Brisbane & Womens Hosp, Dept Med Oncol, Herston, Qld, Australia

[5] Royal Brisbane & Womens Hosp, Dept Gastroenterol, Herston, Qld, Australia

[6] Envoi Pathol, Brisbane, Australia

[7] Queensland Hlth, Conjoint Internal Med Lab, Pathol Queensland, Brisbane, Qld, Australia

[8] Dana Farber Canc Inst, Boston, MA USA

[9] Harvard Med Sch, Dept Pathol, Program MPE Mol Pathol Epidemiol, Brigham & Womens Hosp, Boston, MA USA

[10] Broad Inst MIT & Harvard, Cambridge, MA USA

[11] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA

来源：

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2023年 / 38卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

239

引用

页码：28 / 29

页数：2

共 50 条

[1] KRAS mutant bowel cancers segregate into two distinct subgroups
Borowsky, J.
Su, C.
Fennell, L.
Burge, M.
Leggett, B.
Whitehall, V.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2020, 35 : 188 - 188
[2] Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
Adachi, Yuta
Kimura, Ryo
Hirade, Kentaro
Ebi, Hiromichi
CANCERS, 2021, 13 (20)
[3] GI-4000 in KRAS mutant cancers
Shahda, Safi
O'Neil, Bert
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2014, 23 (02) : 273 - 278
[4] Gene signature of KRAS-mutant cancers
Kabashima, Kenji
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2024, 144 (10) : 2110 - 2110
[5] Therapeutic options for KRAS mutant colorectal cancers
Laffman-Johnson, Elise
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 (02) : 158 - 159
[6] A pan-KRAS degrader for the treatment of KRAS-mutant cancers
Yang, Jie
Wang, Qiao-Li
Wang, Guan-Nan
Ye, Jia-Cong
Li, Zi-Qian
Wang, Jing-Yun
Liang, Zhao-Hui
Li, Shu-Xin
Sun, Cong
Liao, Wen-Ting
Gao, Yi-Jun
Wang, Jing
Mao, Yong
Yu, Chunjing
Feng, Guo-Kai
Zeng, Mu-Sheng
CELL DISCOVERY, 2024, 10 (01)
[7] Distinct metabolic preference of atypical KRAS mutant
Cheong, Heesun
ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (20)
[8] TARGETING RAF KINASES IN BRAF AND KRAS MUTANT CANCERS
Luo, J.
ANNALS OF ONCOLOGY, 2013, 24 : 15 - 15
[9] TRANSLATIONAL RESEARCH FOR TARGETING BRAF AND KRAS MUTANT CANCERS
Ebi, Hiromichi
ANNALS OF ONCOLOGY, 2014, 25
[10] Synthetic Lethal Vulnerabilities in KRAS-Mutant Cancers
Aguirre, Andrew J.
Hahn, William C.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2018, 8 (08):

← 1 2 3 4 5 →